Benign prostatic hyperplasia cell line viability and modulation of JM-27 by doxazosin and ibuprofen

Journal of Urology

Volumn 174, Issue 1, 2005, Pages 375-379

  Minnery, Cynthia H ^a   Getzenberg, Robert H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Fisher Biomarker and Biorepository Laboratory   (United States)

Author keywords

Drug interactions; Ibuprofen; Inflammation; Prostate; Prostatic hyperplasia

Indexed keywords

DOXAZOSIN; GENE PRODUCT; IBUPROFEN; PROTEIN JM 27; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE; GENE EXPRESSION REGULATION; GENE JM 27; HUMAN; HUMAN CELL; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

EID: 20444445530     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000161598.24740.34     Document Type: Article

References (20)

1. Prakash, K., Pirozzi, G., Elashoff, M., Munger, W., Waga, I., Dhir R. et al: Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci USA, 99: 7598, 2002
2. Tammela, T.: Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging, 10: 349, 1997
3. Konig, J. E., Senge, T., Allhoff, E. P. and Konig, W.: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate, 58: 121, 2004
4. Kramer, G., Steiner, G. E., Handisurya, A., Stix, U., Haitel, A., Knerer, B. et al: Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate, 52: 43, 2002
5. Steiner, G. E., Stix, U., Handisurya, A., Willheim, M., Haitel, A., Reithmayr, F. et al: Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest, 83: 1131, 2003
6. Shah, U. S. and Getzenberg, R. H.: Fingerprinting the diseased prostate: associations between BPH and prostate cancer. J Cell Biochem, 91: 161, 2004
7. Taoka, R., Tsukuda, F., Ishikawa, M., Haba, R. and Kakehi, Y.: Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol, 171: 2330, 2004
8. Shah, U. S., Arlotti, J., Dhir, R., Lu, S., Pirozzi, G., Prakash K. et al: Androgen regulation of JM-27 is associated with the diseased prostate. J Androl, 25: 618, 2004
9. Slattery, M. L., Samowitz, W., Hoffman, M., Ma, K. N., Levin, T. R. and Neuhausen, S.: Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev, 4: 538, 2004
10. Roberts, R. O., Jacobson, D. J., Girman, C. J., Rhodes, T., Lieber, M. M. and Jacobsen, S. J.: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc, 77: 219, 2002
11. Garcia Rodriguez, L. A. and Gonzalez-Perez, A.: Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev, 13: 649, 2004
12. Mahapokai, W., van den Ingh, T. S., van Mil, F., van Garderen, E., Schalken, J. A., Mol, J. A. et al: Immune response in hormonally-induced prostatic hyperplasia in the dog. Vet Immunol Immunopathol, 78: 297, 2001
13. Steiner, G. E., Newman, M. E., Paikl, D., Stix, U., Memaran-Dagda, N., Lee C. et al: Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate, 56: 171, 2003
14. Andrews, J., Djakiew, D., Krygier, S. and Andrews, P.: Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol, 50: 277, 2002
15. Monti, S., Di Silverio, F., Toscano, V., Martini, C., Lanzara, S., Varasano, P. A. et al: Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH). J Androl, 4: 428, 1998
16. Andriole, G., Bruchovsky, N., Chung, L. W. K., Matsumoto, A. M., Rittmaster, R., Roehrborn C. et al: Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol, 172: 1399, 2004
17. Kirby, R. S., Roehrborn, C., Boyle, P., Bartsch, G., Jardin, A., Cary, M. M. et al: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 61: 119, 2003
18. McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Jr., Dixon, C. M., Kusek J. W. et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 25: 2387, 2003
19. Kyprianou, N., Litvak, J. P., Borkowski, A., Alexander, R. and Jacobs, S. C.: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol, 159: 1810, 1998
20. Partin, J. V., Anglin, I. E. and Kyprianou, N.: Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer, 88: 1615, 2003